We are live on ! Find out more

Omnicell

OMCL

Market cap $1.53B

33.51 USD

+0.72

2.2%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

33.51

0.00

0%

1 day

2.2%

5 days

-0.71%

1 month

-10.16%

3 months

-16.2%

6 months

-2.27%

Year to date

-25.76%

1 year

3.87%

5 years

-78.8%

10 years

-10.35%

About: Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

Employees: 3,485

Healthcare Health Information Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 38.1%

Neutral 57.1%

Negative 4.8%

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

Integration brings serialized product verification and traceability directly into medication receiving workflows, intended to enable more efficient pharmacy operations without separate compliance processes. BOSTON, Sept.

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference.

Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

Zacks Investment Research

Why Omnicell (OMCL) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Omnicell (OMCL) is a Top Value Stock for the Long-Term

The Motley Fool

Omnicell President Sells 6,753 Shares

The disposal comprised 6,753 shares representing a total transaction value of ~$250,000. The transaction reduced the insider's direct equity holdings by 4%.

Omnicell President Sells 6,753 Shares

Zacks Investment Research

Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins

OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.

Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins

Zacks Investment Research

OMCL Falls 20.1% in a Month as Booking and Margin Risks Build

Omnicell's 20.1% monthly slide reflects booking uncertainty, margin pressure and refresh-cycle risks despite a higher 2026 profit outlook.

OMCL Falls 20.1% in a Month as Booking and Margin Risks Build

Zacks Investment Research

Here's Why Omnicell (OMCL) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Omnicell (OMCL) is a Strong Value Stock

Zacks Investment Research

OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth

Omnicell highlights Titan XT and OmniSphere momentum, and raises profit outlook, while customer approval timing weighs on product bookings.

OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth

EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination

FORT WORTH, Texas--(BUSINESS WIRE)--EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination.

EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination

Omnicell Q2 Earnings Call Highlights

Omnicell NASDAQ: OMCL reported second-quarter 2026 revenue at the high end of its prior outlook and profitability above expectations, while widening its full-year product bookings range to reflect uncertainty in the timing of customer purchasing decisions for large medication-management platform investments.

Omnicell Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™